Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Eur J Cancer ; 159: 1-15, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34700215

RESUMEN

BACKGROUND: The difficulty in interpreting somatic alterations is correlated with the increase in sequencing panel size. To correctly guide the clinical management of patients with cancer, there needs to be accurate classification of pathogenicity followed by actionability assessment. Here, we describe a specific detailed workflow for the classification of the pathogenicity of somatic variants in cancer into five categories: benign, likely benign, unknown significance, likely pathogenic and pathogenic. METHODS: Classification is obtained by combining a set of eight relevant criteria in favour of either a pathogenic or a benign effect (pathogenic stand-alone, pathogenic very strong, pathogenic strong, pathogenic moderate, pathogenic supporting, benign supporting, benign strong and benign stand-alone). RESULTS: Our guide is concordant with the ACMG/AMP 2015 guidelines for germline variants. Interpretation of somatic variants requires considering specific criteria, such as the disease and therapeutic context, co-occurring genomic events in the tumour when available and the use of cancer-specific variant databases. In addition, the gene role in tumorigenesis (oncogene or tumour suppressor gene) also needs to be taken into consideration. CONCLUSION: Our classification could contribute to homogenize best practices on somatic variant pathogenicity interpretation and improve interpretation consistency both within and between laboratories.


Asunto(s)
Neoplasias/genética , Patología Molecular/métodos , Patología Molecular/normas , Humanos , Flujo de Trabajo
2.
JCO Clin Cancer Inform ; 5: 256-265, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33720747

RESUMEN

PURPOSE: Many institutions throughout the world have launched precision medicine initiatives in oncology, and a large amount of clinical and genomic data is being produced. Although there have been attempts at data sharing with the community, initiatives are still limited. In this context, a French task force composed of Integrated Cancer Research Sites (SIRICs), comprehensive cancer centers from the Unicancer network (one of Europe's largest cancer research organization), and university hospitals launched an initiative to improve and accelerate retrospective and prospective clinical and genomic data sharing in oncology. MATERIALS AND METHODS: For 5 years, the OSIRIS group has worked on structuring data and identifying technical solutions for collecting and sharing them. The group used a multidisciplinary approach that included weekly scientific and technical meetings over several months to foster a national consensus on a minimal data set. RESULTS: The resulting OSIRIS set and event-based data model, which is able to capture the disease course, was built with 67 clinical and 65 omics items. The group made it compatible with the HL7 Fast Healthcare Interoperability Resources (FHIR) format to maximize interoperability. The OSIRIS set was reviewed, approved by a National Plan Strategic Committee, and freely released to the community. A proof-of-concept study was carried out to put the OSIRIS set and Common Data Model into practice using a cohort of 300 patients. CONCLUSION: Using a national and bottom-up approach, the OSIRIS group has defined a model including a minimal set of clinical and genomic data that can be used to accelerate data sharing produced in oncology. The model relies on clear and formally defined terminologies and, as such, may also benefit the larger international community.


Asunto(s)
Genómica , Difusión de la Información , Humanos , Oncología Médica , Estudios Prospectivos , Estudios Retrospectivos
3.
J Mol Diagn ; 22(12): 1383-1392, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-33011441

RESUMEN

Genomic sequencing is increasingly used in managing patients with cancer. Interpretation of somatic variants and their pathogenicity is often complex. Pathogenicity prediction tools are commonly used as part of the expert interpretation of somatic variants, but most of these tools were initially developed for germline variants. Our aim was to benchmark their performance for somatic variants. A gold standard list was assembled of 4319 somatic single-nucleotide variants, classified as oncogenic (n = 2996) or neutral (n = 1323), based on their presence in curated databases or on their allele frequency in the general population. These variants were annotated with the most commonly used prediction tools [Database for Nonsynonymous SNPs' Functional Predictions (dbNSFP) and Universal Mutation Database Predictor (UMD-Predictor)] and computed performance calculations. Stratification of the prediction tools based on Matthews correlation coefficient and area under the receiver operating characteristic curve allowed the identification of the top-performing ones, namely, Combined Annotation-Dependent Depletion (CADD), Eigen or Eigen Principal Components (Eigen-PC), Polymorphism Phenotyping version 2 (PolyPhen-2), Protein Variation Effect Analyzer (PROVEAN), UMD-Predictor, and Rare Exome Variant Ensemble Learner (REVEL). Interestingly, Sorting Intolerant From Tolerant (SIFT), which is a commonly used prediction tool for somatic variants, was ranked in the second performance category. Combining tools two by two only marginally improved performances, mainly because of the occurrence of discordant predictions.


Asunto(s)
Biología Computacional/métodos , Frecuencia de los Genes , Neoplasias/genética , Oncogenes , Polimorfismo de Nucleótido Simple , Toma de Decisiones Clínicas/métodos , Exactitud de los Datos , Bases de Datos Genéticas , Exoma , Genes Supresores de Tumor , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Humanos , Mutación Missense , Sensibilidad y Especificidad
4.
Cancer J ; 24(4): 153-162, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30119077

RESUMEN

Comprehensive genomic profiling using high-throughput sequencing brings a wealth of information, and its place in the clinical setting has been increasingly prominent. This review emphasizes the utility of whole-exome sequencing (WES) and transcriptome sequencing (RNAseq) in patient care and clinical research, based on published reports as well as our experience with the MOSCATO-01 (MOlecular Screening for CAncer Treatment Optimization) molecular triage trial at Gustave Roussy Cancer Center. In this trial, all contributive samples of patients with advanced solid tumors were analyzed prospectively with targeted gene sequencing (TGS) and comparative genomic hybridization. In addition, 92 consecutive metastatic patients with contributive biopsies were sequenced for WES and RNAseq and compared with TGS and comparative genomic hybridization. Whole-exome sequencing allowed the reporting of additional variants in relevant genes in 38% of patients. Mutation detection sensitivity of WES was 95% compared with TGS. Additional information derived from WES and RNAseq could influence clinical decision, including fusion transcripts, expression levels, allele-specific expression, alternate transcripts, RNA-based pathogen diagnostic, tumor mutation load, mutational signatures, expression signatures, HLA genotyping, and neoepitope prediction. The current challenge is to be able to process the large-scale data from these comprehensive genome-wide technologies in an efficient way.


Asunto(s)
Secuenciación del Exoma , Neoplasias/diagnóstico , Neoplasias/genética , Transcriptoma , Hibridación Genómica Comparativa , Manejo de la Enfermedad , Detección Precoz del Cáncer , Exoma , Pruebas Genéticas , Variación Genética , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Mutación , Estadificación de Neoplasias
5.
PLoS One ; 12(11): e0188174, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29161279

RESUMEN

Tumor mutation load (TML) has been proposed as a biomarker of patient response to immunotherapy in several studies. TML is usually determined by tumor biopsy DNA (tDNA) whole exome sequencing (WES), therefore TML evaluation is limited by informative biopsy availability. Circulating cell free DNA (cfDNA) provided by liquid biopsy is a surrogate specimen to biopsy for molecular profiling. Nevertheless performing WES on DNA from plasma is technically challenging and the ability to determine tumor mutation load from liquid biopsies remains to be demonstrated. In the current study, WES was performed on cfDNA from 32 metastatic patients of various cancer types included into MOSCATO 01 (NCT01566019) and/or MATCHR (NCT02517892) molecular triage trials. Results from targeted gene sequencing (TGS) and WES performed on cfDNA were compared to results from tumor tissue biopsy. In cfDNA samples, WES mutation detection sensitivity was 92% compared to targeted sequencing (TGS). When comparing cfDNA-WES to tDNA-WES, mutation detection sensitivity was 53%, consistent with previously published prospective study comparing cfDNA-TGS to tDNA-TGS. For samples in which presence of tumor DNA was confirmed in cfDNA, tumor mutation load from liquid biopsy was correlated with tumor biopsy. Taken together, this study demonstrated that liquid biopsy may be applied to determine tumor mutation load. Qualification of liquid biopsy for interpretation is a crucial point to use cfDNA for mutational load estimation.


Asunto(s)
Biomarcadores de Tumor/sangre , Ácidos Nucleicos Libres de Células/sangre , ADN de Neoplasias/sangre , Neoplasias/sangre , Biomarcadores de Tumor/genética , Ácidos Nucleicos Libres de Células/genética , ADN de Neoplasias/genética , Femenino , Humanos , Biopsia Líquida , Masculino , Mutación , Tasa de Mutación , Neoplasias/genética , Secuenciación del Exoma
6.
J Pharmacol Toxicol Methods ; 66(2): 92-7, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22554864

RESUMEN

INTRODUCTION: The occurrence of drug-induced arrhythmias in safety pharmacology or toxicology studies is a primary safety concern. The risk assessment requires an accurate knowledge of background arrhythmia incidence and frequency in the test system/species, as well as a rigorous evaluation of the effects of the potential new medical entities on the electrocardiogram (ECG). However, the direct assessment of arrhythmia in ECG recordings is a time-consuming effort and is rarely achieved due to lack of suitable automated tools. A new software application named ARR30a was developed for fast automated detection in preclinical studies, for the five major arrhythmia types, namely sinus pauses, atrial beats, junctional beats, ventricular beats and type 2 atrio-ventricular blocks (AV-blocks II). The purpose of this study was to characterize the performance of ARR30a in large and small animal species. METHODS: Detection sensitivity and predictivity were evaluated on a database of 84 ECG recordings representative of each animal species and experimental protocols typically used in efficacy, safety pharmacology and toxicology studies. Automated arrhythmia detection was compared with manual analysis. RESULTS: In large animals such as dogs, non-human primates and pigs, ARR30a sensitivity reached 90.6%, 82.2% and 78.0% for ventricular beats, AV-blocks II and junctional beats with predictivity of 83.4%, 94.4% and 93.5%, respectively. Significantly lower sensitivity was observed in rats for junctional beats due to challenging problems of detection for low amplitude P-waves. Robustness to noise was assessed by adding increasing noise levels to ECG signals and showed no significant impact on arrhythmia detection at moderate noise levels. Processing time for a 24 hour recording was approximately 4 min for dogs and 6 min for rats on a 3 GHz processor. DISCUSSION: This newly validated ECG arrhythmia detector ARR30a allows evaluating all major ECG signal abnormalities and enhances the quantification of arrhythmia incidence in all major laboratory animal species. The mark editor RME10a enables manual validation of the automated analysis and refinement of the arrhythmia classification.


Asunto(s)
Arritmias Cardíacas/diagnóstico , Automatización de Laboratorios/métodos , Diagnóstico por Computador/métodos , Evaluación Preclínica de Medicamentos/métodos , Programas Informáticos , Pruebas de Toxicidad/métodos , Algoritmos , Animales , Animales de Laboratorio/fisiología , Arritmias Cardíacas/clasificación , Arritmias Cardíacas/fisiopatología , Automatización de Laboratorios/instrumentación , Perros , Evaluación Preclínica de Medicamentos/instrumentación , Electroencefalografía , Haplorrinos/fisiología , Modelos Animales , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Especificidad de la Especie , Porcinos/fisiología
7.
Nanomedicine (Lond) ; 2(1): 71-8, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17716192

RESUMEN

The development of new imaging probes to noninvasively detect, diagnose and guide therapy for a large variety of diseases is needed. Quantum dots are highly fluorescent and photostable nanoparticles that are finding increasing applications as imaging probes. We have conjugated quantum dots to annexin A5, in order to develop a sensor for detecting apoptotic cells. The sensor specifically recognizes phosphatidylserine on the extracellular leaflet of the plasma membrane through the annexin A5. This quantum dot-based sensor allows increased sensitivity of detection and continuous monitoring of apoptotic cells over time periods that are longer than previously possible.


Asunto(s)
Anexina A5/farmacocinética , Apoptosis/fisiología , Membrana Celular/fisiología , Membrana Celular/ultraestructura , Microscopía Fluorescente/métodos , Fosfatidilserinas/metabolismo , Puntos Cuánticos , Anexina A5/química , Técnicas Biosensibles/métodos , Células HeLa , Humanos , Aumento de la Imagen/métodos , Ensayo de Materiales
8.
Cancer Chemother Pharmacol ; 57(4): 491-9, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16075278

RESUMEN

PURPOSE: This study assessed the cytotoxic effects of irofulven in combination with oxaliplatin and cisplatin in a panel of human cancer cell lines. METHODS: Growth inhibition studies were performed using the human HT29 colon cancer cell line, irofulven-resistant derivative HT29/IF2, breast cancer cell line MCF7, and ovarian cancer line CAOV3. Irofulven-oxaliplatin combinations were compared with irofulven-cisplatin combinations in the same cell lines using similar experimental settings. Cells were exposed for 1 h to irofulven and then for 24 h to oxaliplatin or cisplatin and vice versa. RESULTS: Single agent irofulven displayed cytotoxic effects against human colon HT29 cells, human breast cancer cell lines including MCF7, SKBR3, and ZR-75-1, and human ovarian cancer cell lines CAOV3, OVCAR3, and IGROV1, with OVCAR3 being the most sensitive cancer cell line (IC50: 2.4 microM). In all tested cell lines the oxaliplatin-irofulven combination led to clear evidence of synergistic activity. In HT29 and HT29/IF2, the sequence oxaliplatin followed by irofulven appears to be the most effective whereas in MCF7 cells, irofulven given prior to or simultaneously with oxaliplatin is more effective than the other schedule. The combination displays additive activity toward CAOV3 ovarian cells when irofulven was administered prior to or simultaneously with oxaliplatin and partially synergistic when oxaliplatin was followed by irofulven. In most of the cell lines, the sequence oxaliplatin followed by irofulven appears to be the most effective as compared to other schedules. A combination of irofulven with cisplatin has the same efficacy as with oxaliplatin for the same cell lines. Cell cycle studies show that irofulven increases the proportion of cells in the S phase. Cisplatin-irofulven and oxaliplatin-irofulven combinations block cells in G1/S and potently induce apoptosis. CONCLUSION: Irofulven displays synergistic antiproliferative and pro-apoptotic effects when combined with oxaliplatin over a broad range of concentrations in human colon and breast cancer cells. Acquired resistance to irofulven has limited impact on the effects of cisplatin-irofulven and oxaliplatin-irofulven combinations. Based on these data, irofulven-oxaliplatin and cisplatin-irofulven combinations will be further explored in clinical trials, favoring the use schedules of oxaliplatin given prior to irofulven in patients with cancer.


Asunto(s)
Antineoplásicos Alquilantes/toxicidad , Antineoplásicos/toxicidad , Neoplasias de la Mama/tratamiento farmacológico , Cisplatino/toxicidad , Neoplasias del Colon/tratamiento farmacológico , Compuestos Organoplatinos/toxicidad , Neoplasias Ováricas/tratamiento farmacológico , Sesquiterpenos/toxicidad , Algoritmos , Apoptosis/efectos de los fármacos , Neoplasias de la Mama/genética , Neoplasias de la Mama/patología , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Neoplasias del Colon/genética , Neoplasias del Colon/patología , Resistencia a Múltiples Medicamentos , Resistencia a Antineoplásicos , Sinergismo Farmacológico , Femenino , Genes p53/genética , Células HT29 , Humanos , Neoplasias Ováricas/genética , Neoplasias Ováricas/patología , Oxaliplatino , Sales de Tetrazolio , Tiazoles
9.
Clin Cancer Res ; 10(16): 5604-13, 2004 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-15328203

RESUMEN

BACKGROUND: Irofulven is a novel alkylating agent with promising clinical activity, particularly toward ovarian and hormone-refractory prostate cancers. To facilitate additional clinical development, we have aimed to identify biological markers associated with sensitivity to the compound. METHODS: Fibroblasts derived from patients with xeroderma pigmentosum or Cockayne's syndrome along with a panel of 20 human cancer cell lines (eight different tumor types) were examined to establish the importance of nucleotide excision repair proteins in the sensitivity to irofulven. RESULTS: Human cells deficient in nucleotide excision repair are up to 30-fold more sensitive to the cytotoxic effects of irofulven compared with repair-proficient controls, clearly indicating that nucleotide excision repair plays a crucial role in the sensitivity to the drug. Interestingly, our results show that irofulven-induced lesions are recognized by transcription-coupled repair but not by global genome repair. Another unique feature is the pronounced sensitivity of XPD and XPB helicase-deficient cells to the drug. Comparison of the IC50 values for irofulven, cisplatin, and ecteinascidin 743 with the expression levels of ERCC1, XPD, and XPG genes in different solid tumor cell lines shows no correlation between the expression levels of any of the three nucleotide excision repair proteins and the sensitivity to ecteinascidin 743. In contrast, expression of the XPG endonuclease was correlated with the cytotoxicity for irofulven and, to a lesser degree, for cisplatin. Importantly, XPG expression was also correlated with cellular nucleotide excision repair activity. CONCLUSIONS: Increasing evidence indicates that compromised nucleotide excision repair activity is frequent in several solid tumor types. The results presented here suggest that XPG expression in such tumors may be a useful marker to predict their sensitivity to irofulven.


Asunto(s)
Supervivencia Celular/efectos de los fármacos , Reparación del ADN/genética , Proteínas de Unión al ADN/genética , Sesquiterpenos/toxicidad , Transcripción Genética/genética , Antineoplásicos Alquilantes/toxicidad , Secuencia de Bases , División Celular/efectos de los fármacos , Línea Celular Tumoral , Células Cultivadas , Síndrome de Cockayne/genética , Síndrome de Cockayne/patología , Cartilla de ADN , ADN de Neoplasias/genética , Endonucleasas , Humanos , Proteínas Nucleares , Factores de Transcripción , Transcripción Genética/efectos de los fármacos , Xerodermia Pigmentosa/genética , Xerodermia Pigmentosa/patología
10.
Int J Oncol ; 23(5): 1347-55, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-14532976

RESUMEN

Irofulven (6-hydroxymethylacylfulvene, MGI-114, NSC 683863) is a semisynthetic derivative of illudin S, a natural product obtained from the Omphalotus mushroom. Irofulven has demonstrated potent activity against a broad range of solid tumors in both cellular and xenograft models and has shown promising activity in clinical trials. To guide the clinical use of irofulven, the present study used the MTT viability assay to examine the cytotoxic effects obtained by combining irofulven with two other anticancer agents: cisplatin and 5-fluorouracil (5-FU). The study was carried out with HT-29 and HCT-116 colorectal and A2780 ovarian carcinoma cells as well as with their irofulven- (HT-29/IF2, HCT-116/IF27) or cisplatin-resistant (A2780/CP70) variants. The combinations showed strong sequence specificity. Simultaneous exposure to cisplatin and irofulven was at least additive for four cell lines including the cisplatin-resistant A2780/CP70 ovarian cells which exhibit a multifactorial resistance phenotype. Cisplatin followed by irofulven was additive for parental HCT-116 and A2780 cells whereas irofulven followed by cisplatin was antagonistic in all cellular models. Simultaneous exposure to 5-FU and irofulven was at least additive for all six cell lines. 5-FU followed by irofulven was additive for the parental HT-29 and A2780 cells and synergistic for the irofulven-resistant HCT-116 cell line. Irofulven followed by 5-FU was synergistic for the two ovarian cell lines and additive for the two parental colon cell lines. These studies demonstrate that simultaneous exposure to irofulven and cisplatin is at least additive for most cell lines whereas simultaneous exposure to irofulven and 5-FU is additive to synergistic for all the cell lines tested, including the irofulven- and cisplatin-resistant variants. The enhanced cytotoxicity of irofulven in combination with cisplatin and 5-FU support the clinical application of these regimens.


Asunto(s)
Antineoplásicos/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma/tratamiento farmacológico , Cisplatino/administración & dosificación , Fluorouracilo/administración & dosificación , Neoplasias Ováricas/tratamiento farmacológico , Sesquiterpenos/administración & dosificación , Antimetabolitos Antineoplásicos/administración & dosificación , Antineoplásicos/administración & dosificación , Antineoplásicos Alquilantes/administración & dosificación , Línea Celular Tumoral , Cisplatino/farmacología , Colorantes/farmacología , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Concentración 50 Inhibidora , Modelos Químicos , Sales de Tetrazolio/farmacología , Tiazoles/farmacología
11.
Clin Cancer Res ; 9(7): 2817-25, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12855662

RESUMEN

PURPOSE: To characterize the activities of irofulven, a novelanticancer agent derived from the mushroom natural productilludin S toward human cancer cells. EXPERIMENTAL DESIGN: We have determined the activity spectrum of irofulven toward a human tumor cell panel comprised of 10 different tumor types in comparison with cisplatin and ET-743. We have also evaluated the influence of major resistance mechanisms, such as expression of multidrug resistance-associated drug efflux pumps, cisplatin resistance, loss of p53 function, and absence of mismatch repair on the cytotoxic activity of irofulven. RESULTS: The activity spectrum of irofulven is clearly different from that of ET-743 and cisplatin. Irofulven shows excellent cytotoxicity toward the majority of human carcinoma cell lines tested, but lesser activity toward sarcoma and leukemia cell lines. The cytotoxic activity of irofulven was particularly pronounced toward head and neck, non-small cell lung, colon, and ovary carcinoma cells, as well as toward malignant glioma cell lines. In addition, irofulven displayed good activity toward poorly differentiated, androgen-independent prostate cancer cells and cell lines expressing high levels of the detoxifying enzymes glutathione S-transferase and gamma-glutamyl cysteine synthetase. The cytotoxicity of irofulven was not affected by loss of p53 or mismatch repair function, and the drug was not a substrate for multidrug transporters, such as the P-glycoprotein and multidrug resistance protein 1. CONCLUSIONS: Irofulven has an unusual activity spectrum with strong activity toward tumor cells of epithelial origin. Furthermore, irofulven is not or only marginally affected by resistance mechanisms limiting the efficacy of other alkylating agents.


Asunto(s)
Carcinoma/metabolismo , Cisplatino/farmacología , Dioxoles/farmacología , Isoquinolinas/farmacología , Sesquiterpenos/farmacología , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/biosíntesis , Antibióticos Antineoplásicos/farmacología , Antineoplásicos Alquilantes/farmacología , Western Blotting , Línea Celular Tumoral , Medios de Cultivo/farmacología , Resistencia a Antineoplásicos , Células Epiteliales/metabolismo , Glutamato-Cisteína Ligasa/biosíntesis , Glutatión Transferasa/biosíntesis , Humanos , Modelos Químicos , Extractos Vegetales/farmacología , Sesquiterpenos Policíclicos , Tetrahidroisoquinolinas , Factores de Tiempo , Trabectedina , Proteína p53 Supresora de Tumor/metabolismo , Proteínas de Unión al GTP rho/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...